INVOKANA ® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news